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Summary
Background: Most patients only have three mea-
surements of blood pressure before being labelled as
hypertensive. This may lead to inaccurate classifica-
tion, unnecessary treatment and dilution in treat-
ment benefit for the population.
Aim: To examine the accuracy of current methods
of diagnosing mild hypertension, and to explore
ways to improving targeting of antihypertensive
treatment without entailing lengthy observation.
Design: Re-analysis of published data.
Methods: We tested current diagnostic methods
using the data for 3965 individuals who were
followed for a year in the placebo arm of the MRC
Mild Hypertension Trial. We calculated the propor-
tion selected for treatment by current methods
and the diagnostic accuracy, using average blood
pressure beyond 6 months as representing ‘true’
long-term blood pressure. We examined the benefit
of averaging blood pressures, of prolonging
observation modestly and of estimating within-
person blood pressure variability.
Results: Prolonging observation to 3 months selects
a smaller (by about 12%) proportion of the sample
for treatment, a proportion similar to that defined
as ‘truly’ hypertensive. The diagnostic accuracy
of current methods is poor, with up to 69%
discrepancy in classification. This discrepancy
was improved by up to 18% in absolute terms
by prolonging observation to 3 months and using
average blood pressures. Identifying those indivi-
duals with low within-person variability allows
marked improvement in the prediction of ‘true’
hypertension.
Discussion: Although some inaccuracy in the diag-
nosis of hypertension is inevitable, observation for
3 months, averaging blood pressures and estimating
within-person blood pressure variability can mark-
edly improve upon current practice.
Introduction
Current guidelines for the management of hyper-
tension1 recommend prolonged observation of
patients with mild hypertension before initiation of
treatment. The main reason for this is the notion that
‘falsely hypertensive’ patients will be ‘weeded out‘,
and unnecessary treatment avoided. However, the
guidelines do not specify the precise length of
observation needed, nor do they advise whether the
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last single measurement obtained or the average of
several should be used for decision-making. Data
from the UK in the early 1990s suggested that
doctors treating hypertensives did not follow the
guidelines, as up to 90% of those labelled hyper-
tensive had fewer than three measurements before
the diagnosis was made.2,3 This practice appears not
to have improved recently,4–6 and the implementa-
tion of guidelines may not have had the hoped-for
impact on patient outcomes.7 We thus still need
simple and speedy methods for improving classifi-
cation of individuals, which also would benefit
society as a whole.
The current practice in labelling of hypertensives
is not very different from the selection procedure
used in the MRC trial of treatment in mild
hypertension,8 and in this study we have examined
how accurate current practices2,3 are in the
diagnosis of mild hypertension, by applying them
to the placebo arm of the MRC trial database. We
suggest three simple steps that would improve the
targeting of antihypertensive treatment without the
need for lengthy observation.
Methods
Study population
We had available the first year’s blood pressures for
8654 individuals in the placebo arm of the MRC
trial, of whom 3965 had complete follow-up data
and were included in the current analysis. In the
MRC trial,8 blood pressure was measured in existing
urban GP clinics by trained observers, using
Hawksley random zero sphygmomanometers, thus
minimizing technique-related errors and observer
bias. Four assessments of blood pressure were made
before randomization, the average of the first
two being entered as the ‘screening’ pressure and
the average of assessments 3 and 4 as the ‘entry’
pressure. Individuals were included in the study if
‘entry’ diastolic blood pressure was 90–109mmHg
and systolic blood pressure < 200mmHg. Follow-up
visits were at weeks 2, 4, 6, 8, 10, 12, 26, 39 and 52.
For the purpose of this analysis, we have
chosen diastolic blood pressure  90mmHg or
 100mmHg, and systolic blood pressure
 160mmHg as denoting hypertension. To repre-
sent current practices for diagnosing hypertension,
we chose follow-up blood pressure at week 2 (third
blood pressure in database, but in fact the fifth visit).
As average blood pressure correlates better than
single readings with target organ damage,9 and no
guidelines advise observation beyond 6 months, we
have selected the average blood pressure of three
visits at weeks 26, 39 and 52 as representing ‘true’
long-term blood pressure (i.e. beyond 6 months).
Proportion of sample selected
for treatment
First, we looked at the proportion of the total sample
that would be selected for treatment according to
the above defined thresholds if current practices2,3
were applied to the database. Second, we looked at
the proportion that would be selected for treatment
by the average blood pressure of the last three visits
after 3 months observation. Both methods were then
compared to the proportion of the sample that was
‘truly’ hypertensive (i.e. according to average blood
pressure beyond 6 months).
Diagnostic accuracy
Clinic blood pressure exhibits considerable within-
person variability, and thus even though the overall
percentage of hypertensive subjects may be con-
stant, each individual might be classified as
hypertensive at one particular time point but
normotensive at another (and vice versa). We
looked at the extent of this by calculating the
diagnostic accuracy for (i) current practices and (ii)
classification based on the average blood pressure
of the last three visits after 3 months observation.
The diagnostic accuracy was defined as the
percentage of individuals in a category initially
that fell into the same category at a second
assessment. The second reference assessment was
the ‘true’ long-term blood pressure beyond 6
months.
Probability of ‘true’ hypertension
It would be helpful if it were possible to identify
early (and easily) subgroups of individuals who were
most likely not to change their blood pressure in the
long term (i.e. those with low within-person blood
pressure variability). To this end, we calculated the
probability of ‘true’ long-term hypertension, using
diastolic blood pressure  100mmHg to define
hypertension, as this is an universally accepted
indication for pharmacological treatment.10–12
We first calculated the probability of long-term
hypertension as predicted by current practices, and
then as predicted by average blood pressure after
3 months follow-up, combined with low within-
person blood pressure variability.
As a measure of within-person variability in blood
pressure, we calculated the coefficient of variation
(CV) for the blood pressure values obtained at
the last 3 visits after 3 months observation period
(CVBP¼ SD/mean 100). The bottom quartile of
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CVBP defined those individuals with the lowest
within-person variability in blood pressure.
Results
Proportion of sample selected
for treatment
The proportion of the sample selected for treatment
depended on the threshold chosen and length of
observation (Table 1). Current practices of initiating
hypertension treatment at or before obtaining three
blood pressure values, select a significantly larger
proportion (about 10–12%) of the sample for
treatment, than would be selected by follow-up
beyond 6 months. However, simply prolonging
observation to 12 weeks and using the average of
the last three visits, selected a very similar propor-
tion for treatment as would have been selected if
the observation time had been prolonged to beyond
6 months.
Diagnostic accuracy
For current practices, the accuracy of diagnosis
varied from 31% to 92% (Figure 1), depending on
the threshold chosen, and whether the analysis was
done for pressures initially higher or initially lower
than the threshold. This means that the currently
widespread practice of initiating treatment after only
three visits may lead to unnecessary treatment in up
to 69% of individuals (for  100mmHg diastolic
initially). There was an absolute improvement in
classification discrepancy rates of up to 18% from
prolonging observation to 3 months and using
average of the last three visits for classification.
The greatest improvement was noted for pressures
initially higher than the thresholds. However,
diagnostic accuracy remained fairly poor in spite
of this improvement. For example, only 47% of
individuals initially with average diastolic blood
pressure  100mmHg remained in that category
after 1 year of observation, and in fact this
figure does not improve with longer follow up, e.g.
comparing week 39 with week 52 (data not shown).
Probability of ‘true’ hypertension
Median CVBP was 5.0, with the 25
th percentile at
3.1. For current practices, the probability of ‘true’
hypertension (long-term diastolic blood pressure
 100mmHg) was 0.23 if initial diastolic blood
pressure was in the range 100–104mmHg (Figure 2).
Prolonging the follow-up period to 3 months
and using average blood pressure in combination
with low within-person variability (CVBP < 3.1),
increased the probability to 0.40 for initial diastolic
blood pressure in the range 100–104mmHg. It can
be seen from Figure 2 that the higher the initial
blood pressures, the higher the probability of long-
term blood pressure remaining  100mmHg. How-
ever, the probability remains at best about 0.43 for
current GP practices, and is at best about 0.70 for
those who have low within-person variability and
average initial (here, although actually the fifth visit)
blood pressure  112mmHg.
Table 1 The proportion of the sample selected for treatment by current GP practice, and by mean
blood pressure (BP) after 3 months, compared to the ’true’ proportion of hypertensives*
Threshold Current practice Mean BP after 3 months ‘Truly’ hypertensive*
DBP 90mmHg 67.6 1.5 55.5 1.6 57.8 1.5
DBP 100mmHg 24.9 1.4 13.8 1.1 12.5 1.0
SBP 160mmHg 25.9 1.4 15.4 1.1 18.5 1.2
Data are percentages 95%CIs. DBP, diastolic blood pressure; SBP, systolic blood pressure.
*See Methods for definition.
Figure 1. Diagnostic accuracy (see text for definition).
Open symbols relate to current GP practices. Closed
symbols indicate the accuracy if average blood pressure of
the last three visits of 3 months observation was used for
diagnosis. DBP, diastolic blood pressure; SBP, systolic
blood pressure (both in mmHg). Error bars indicate
95%CIs.
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Life-long treatment with several drugs usually
follows the diagnosis of hypertension. This diagnosis
therefore needs to be as accurate as possible. The
MRC trial of mild hypertension, defined as systolic
blood pressure < 200mmHg and diastolic blood
pressure of 90–109mmHg, showed that 850 indivi-
duals need to be treated for one year in order to
save one stroke (so-called number needed to treat,
NNT)—a very high figure compared to some other
forms of primary cardiovascular disease preven-
tion.13,14 However, this figure is probably an
underestimate of the potential benefit of antihyper-
tensive treatment, caused by the brief selection
procedure, and could be lowered with more careful
and better targeting of patients.15
At present, the majority of those labelled as
hypertensive have had only 2–3 estimates of their
blood pressure before the initiation of antihyperten-
sive treatment,2,3 which is broadly comparable to
the selection procedure used in the MRC trial of
mild hypertension.8 In this paper, we have applied
current methods of diagnosing hypertension to the
placebo arm of the MRC trial, and found that this
leads to very poor targeting of treatment.
Considering the treatment threshold of
 100mmHg diastolic, current methods not only
select an excessive proportion of the population for
treatment (by 10–12%, Table 1), but also incorrectly
classify up to 69% of the individuals (Figure 1).
Better targeting would lower NNT, as is recognized
by current guidelines8,16 recommending prolonged
observation for up to 6 months. However, we
believe that 6 months is unduly long, risking loss
to follow-up, and previous estimates have suggested
that blood pressure in populations does not change
much beyond 3–4 months16 or after six separate
visits.17 The analysis presented here shows that if
blood pressure is assessed eight times over only 3
months and the average of the last three visits is
used for classification, then the proportion of the
sample selected for treatment is similar to that after a
whole year’s follow-up (Table 1). This initial fall in
the proportion selected for treatment is most likely
due to regression to the mean, and habituation to
repeated measurements. With still longer follow-up,
there may be minor fluctuations in the percentage
selected for treatment in such a large sample, but the
clinical relevance of those is doubtful.
A major corollary of the current analysis is that
although the proportion of the population selected
seems to have reached equilibrium at 3 months, we
are not selecting the same individuals for treatment
at different time points. Thus the diagnostic accu-
racy of current methods for initial diastolic blood
pressure 100mmHg was only 31% (69% of those
patients are not ‘truly’ hypertensive, see Figure 1).
The diagnostic accuracy is in reality likely to be
even lower, since in the MRC-trial, observer bias
and technique-related errors have been minimized,
and the blood pressure in the database used to
represent the value GP’s currently act on was in fact
the fifth visit in the trial. Our suggestion, to prolong
observation to 3 months, resulted in a considerable
improvement (up to 18%) in the diagnostic accu-
racy, but accuracy was still poor, for example,
for those initially with diastolic blood pressure
 100mmHg (Figure 1). The population studied
was selected on the basis of blood pressures being
higher than the population average, and therefore
part of the discrepancy in classification will be
explained by regression to the mean, e.g. for blood
pressures higher than the threshold chosen. How-
ever, the inherent blood pressure variability of each
individual also plays a role, and given the contin-
uous blood pressure distribution in the population, a
degree of imprecision in the diagnosis of hyperten-
sion is inevitable.
It is not surprising that those with blood pressure
much higher than the treatment threshold are more
likely to remain in that category, i.e. being correctly
identified as hypertensive. However, the probability
of being correctly identified as hypertensive is at
best about 0.4 if current methods in General
Practice are used (Figure 2). We can improve
markedly on this by prolonging observation to
3 months, using average blood pressures and
Figure 2. ‘True’ hypertension is defined as diastolic blood
pressure 100mmHg beyond 6 months of follow-up.
The dotted line indicates the probability of correct
diagnosis according to methods currently used for
ranges of blood pressure as indicated. The thin solid line
indicates the probability calculated by using average
blood pressures from the last three visits of 3 months
follow up, while the thick solid line represents the same
group but now including only those with CVBP < 3.1 (25
th
percentile).
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calculating CVBP. Those exhibiting very low intra-
personal variation in blood pressure (solid thick line
in Figure 2) as defined by CVBP < 3.1, still represent
25% of the individuals in the MRC trial. In spite
of this marked improvement in the prediction of
sustained hypertension, the probability of correct
identification is still at best only about 0.7. Calcula-
tion of CVBP is a simple and quick task, using a
modern calculator, most of which have an auto-
matic facility for calculating standard deviation.
Implicit in the results of this analysis is an
observation that we require better methods for
diagnosing mild hypertension. Ambulatory blood
pressure monitoring allows collection of multiple
readings without the potential loss to follow-up
that is seen in clinical practice. Reproducibility of
ambulatory blood pressure monitoring is reported to
be twice that of clinic measurement,18 is not subject
to habituation to repeated measurements19 and
identifies the problem of ‘white coat’ hyperten-
sion.20 The improved precision of this technique
may thus lead to a more rapid identification of those
patients with ‘true’ hypertension who would benefit
most from anti-hypertensive therapy.21 While ambu-
latory blood pressure monitoring may at present
be beyond the reach of most primary practitioners,
self monitoring of blood pressure at home is an
alternative,22 or one can adopt these three simple
steps, which can markedly improve on current
practices used for targeting antihypertensive treat-
ment: (i) assessment of blood pressure eight times
over 3 months; (ii) classification of patients using
the average blood pressure of the last three visits;
and (iii) estimation of within-person blood
pressure variability by calculation of coefficient of
variation.
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